ModifiedEmblemHealthPolicy AHS-G2031

Allergen Testing Lab Benefit Program (LBM)

Defines coverage, limitations, and reimbursement guidance for in-vitro and related allergen testing for EmblemHealth members, including which tests meet or do not meet coverage criteria and applicable testing limits.

Policy Summary

PayerEmblemHealth

PolicyAllergen Testing Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2031

Change TypeLBM expansionclarifying reorganization of coverage criteriamaterial changes included

Effective DateMar 1, 2023

Next Review DateN/A

Key ActionLimit specific IgE in‑vitro testing to allergens selected from the patient's history, exam, and environment and cap testing at up to 20 allergen‑specific antibodies per year.

SourceLink

POLICY UPDATE CHANGES

Policy updated for clarity with no change to clinical or coding criteria; Coverage Criteria reorganized (former Coverage Criteria 2 became Coverage Criteria 1) and Coverage Criteria 8 was absorbed into Coverage Criteria 7.

Lab Benefit Program (LBM) expanded to include EmblemHealth HMO/PPO (Non-City) Commercial, Medicare and Medicaid plans effective 10/1/2024.

Removed Coverage Criteria 1 (clinical guidance only) and a Note defining contraindications associated with that removal.

up to 20allergen specific antibodies covered per year

annualre-testing for monitored food allergy

not coveredALCAT test coverage status

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Americans affected by allergies

2024-10-01Effective expansion date for LBM

Coverage Criteria for Allergen Testing

Coverage criteria for allergen testing

Coverage decisions for allergen testing are tied to clinical presentation and member benefits; Medicare/Medicaid specifics referenced elsewhere in this policy.

Total serum IgE: Meets coverage when used for individuals with moderate to severe asthma or for individuals with signs or symptoms of allergic bronchopulmonary aspergillosis (ABPA).

Monitoring food allergy resolution in children/adolescents: Annual re‑testing for the same food allergen(s) meets coverage when performed to monitor for resolution after an initial positive food allergen result(s).

Routine re‑testing: In the absence of a new clinical presentation, routine re‑testing for allergies to the same allergens (except where specified above) does not meet coverage.

Excluded / not covered tests

ALCAT: Antigen leukocyte antibody test (ALCAT) does not meet coverage criteria due to lack of reproducible clinical evidence.
Basophil activation and non‑IgE immunoglobulins: Basophil activation flow cytometry testing and in‑vitro testing of IgG, IgA, IgM, and/or IgD do not meet coverage criteria for individuals with signs or symptoms of allergies.
Bead‑based epitope assays (e.g., VeriMAP Peanut Dx) do not meet coverage criteria as emerging technologies requiring additional validation.
Qualitative multi‑allergen screens: In‑vitro qualitative specific IgE multi‑allergen screens that do not identify a specific allergen do not meet coverage criteria.

Coverage-related recommendations

Professional society recommendations and evidence summaries informing appropriate use of allergy testing.

Preferred primary diagnostics: Prefer skin prick testing (SPT) when feasible; use serum‑specific IgE immunoassays when skin testing is unsafe or impractical (e.g., widespread skin disease, interfering medications, uncooperative patients, or high anaphylaxis risk).

Tests to avoid: Do not perform IgG or IgG subclass testing for food allergy; avoid indiscriminate or routine broad batteries of IgE tests in evaluation of allergy (Choosing Wisely recommendations).

Component testing for peanut: Consider component testing (e.g., Ara h 2) for peanut when a single diagnostic test is chosen due to superior diagnostic accuracy; recognize lower sensitivity compared with SPT or whole‑peanut sIgE and do not routinely add component testing to improve accuracy when SPT or sIgE are already used.

Role of BAT: Basophil activation testing (BAT) may be useful as a second‑step test after equivocal SPT or component/sIgE results to reduce the need for oral food challenge and to assess severity/threshold in peanut allergy (selective specialist use).

Coverage criteria and appropriate use

Diagnostic testing should be guided by clinical history and physical examination; routine broad panels and nonstandardized tests are discouraged. Specific modalities are appropriate in defined circumstances.

History and exam first: Clinician should complete a detailed allergy‑focused history and physical examination prior to testing; test selection must be informed by that evaluation.

Primary diagnostic modalities: Use SPT or serum sIgE to confirm sensitization when history is consistent with allergic rhinitis or suspected food allergy; prefer serum sIgE when SPT is not feasible or unsafe.

Avoid routine broad/multiplex panels: Routine use of large food allergen panels or multiplex testing (e.g., ImmunoCAP ISAC) is not recommended because of limited positive predictive value; testing should be targeted to suspected allergens based on history.

Advanced/specialist tests limited: Component resolved diagnostics, BAT, nasal sIgE, nasal provocation testing and other advanced diagnostics may be considered by specialists or when first‑line tests are inconclusive, but are not for routine use.

Coverage and reimbursement criteria overview

Reimbursement policy establishes covered procedure codes, LBM program scope, and clinical prerequisites; revisions updated program scope and reorganized coverage criteria without changing clinical or coding criteria.

Procedure codes and billing references: Certain allergen testing procedure codes (CPT/HCPCS and proprietary U codes) are listed for reimbursement reference under the LBM program, including CPT codes for specific IgE, total IgE, immunoassays, flow cytometry markers, and proprietary VeriMAP U‑codes.

Pre‑testing and competency prerequisites: Testing must be performed only after an allergy‑focused clinical history and by clinicians with competencies to select, perform, and interpret tests; skin testing requires facilities to manage anaphylaxis.

Regulatory precedence: If there is a conflict between this policy and applicable government policy (e.g., LCD/NCD or state Medicaid), the government policy governs coverage determinations.

Program scope and revisions:

Coding and Procedure Codes

Applicable coding guidance and editingmixed

No codes listed

Recommended antigen panel sizemixed

Minimum antigen panel recommendation: at least 23 antigens for seasonal allergen classes to optimally detect sensitization

Diagnostic test coding considerationsmixedCovered

Skin prick testing (SPT) and serum allergen-specific IgE recommended as primary diagnostics; component-resolved diagnostics as specialist option.

Standard lab procedure codesCPT | HCPCS | mixed

82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
82785	Gammaglobulin (immunoglobulin); IgE
82787	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
86003	Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each
86005	Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card)

Component and proprietary assay codesCPT | HCPCS | mixed

86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component; each
0165U	Peanut allergen-specific quantitative assessment of multiple epitopes enzyme-linked immunosorbent assay (ELISA), blood; individual epitope results and probability of peanut allergy (Proprietary VeriMAP Peanut Dx Bead-based Epitope Assay)
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood; report of minimum eliciting exposure for a clinical reaction (Proprietary VeriMAP Peanut Sensitivity Bead Based Epitope Assay)
88184	Flow cytometry; technical component only; first marker
88185	Flow cytometry; technical component only; each additional marker

inv-10: Allergen-specific IgE test limit — up to 20 allergen-specific antibodies per year

Annual limitUp to 20 allergen-specific antibodies per member per year

Condition for coverageTests limited to allergens chosen based on an individual's history, physical exam, and environment

Exception for monitoringAnnual re-testing for the same food allergen(s) meets coverage when monitoring resolution in children/adolescents with prior positive result

inv-11: BAT CD63 peanut/anti-IgE ratio — threshold associated with increased risk

Threshold (CD63 peanut/anti-IgE)>= 1.3 is associated with increased risk of severe reactions (relative risk 3.4)

Provider Actions, Requirements, and Testing Guidance

Prior Authorization

Test selection guidance — use history and physical to guide selection; alternatives when skin testing unsafe

Select allergen tests guided by an allergy‑focused history and physical examination, including consideration of the patient’s age, environment, occupation, activities, and regional allergen exposure. Use history and exam to limit testing to allergens plausibly responsible for the patient’s symptoms; indiscriminate or broad panel testing without clinical indication is not appropriate. When skin testing is unsafe or impractical (for example, widespread dermatitis, patients receiving skin‑test suppressive therapy, uncooperative patients, or when the history suggests a high risk of anaphylaxis), serum allergen‑specific IgE (sIgE) testing is an acceptable alternative. Do not perform allergy testing without first taking and documenting an allergy‑focused clinical history. Interpret all test results in the context of the clinical history; test results alone do not establish a diagnosis.

Limit in‑vitro specific IgE testing to allergens chosen based on history, exam, and environment (coverage: up to 20 specific IgE tests per year when clinically indicated).
Use sIgE testing when skin testing is contraindicated or unsafe.
Avoid routine repeat testing for the same allergens in the absence of a new clinical presentation (exceptions include annual re‑testing to monitor food allergy resolution in children/adolescents with prior positive results).

Key Terms and Acronyms

inv-21: Key terms and acronyms — list of commonly used abbreviations (IgE, AAAAI, ALCAT, BAT, SPT, OFC, LDTs)

IgEImmunoglobulin E (IgE)

BATBasophil activation test (BAT)

SPTSkin prick test (SPT)

sIgESpecific immunoglobulin E (sIgE) — serum allergen-specific IgE

LDTLaboratory-developed tests (LDTs)

AAAI/ACAAIAmerican Academy of Allergy, Asthma, and Immunology (AAAI) / American College of Allergy, Asthma, and Immunology (ACAAI)

Policy Summary

PayerEmblemHealth

PolicyAllergen Testing Lab Benefit Program (LBM)

Policy CodePolicy AHS-G2031

Change TypeLBM expansionclarifying reorganization of coverage criteriamaterial changes included

Effective DateMar 1, 2023

Next Review DateN/A

Key ActionLimit specific IgE in‑vitro testing to allergens selected from the patient's history, exam, and environment and cap testing at up to 20 allergen‑specific antibodies per year.

SourceLink

On This Page

Total IgE use: Total serum IgE should not be used routinely to diagnose food allergy; it may have limited use to assess atopic status or in selected therapeutic decisions.

Competency requirement: All testing should be performed and interpreted by healthcare professionals with appropriate competencies; skin testing must be performed where facilities exist to manage anaphylaxis.

Policy revisions expanded the Lab Benefit Program to additional EmblemHealth plan types effective 10/01/2024 and reorganized coverage criteria; the revision history documents clarifications without changing clinical or coding criteria.

Component and proprietary assay references: Coverage references include component‑resolved testing and proprietary assays (e.g., VeriMAP) with associated U‑codes provided for billing reference; these technologies have specific coverage stances noted elsewhere in the policy.

External guidance cited: Policy cites multiple external clinical resources (e.g., NICE, EAACI, WAO, AAAAI) regarding appropriate use and limitations of multiplex and in‑vitro testing.

Clinical implicationHigher CD63 peanut/anti-IgE ratios correlate with basophil reactivity and greater severity during oral food challenges

Source contextFindings derived from peanut OFC cohort assessing BAT performance

inv-12: BAT CD-sens — threshold associated with increased risk

Threshold (CD-sens)>= 84 associated with increased risk of reacting to <= 0.1 g peanut protein (relative risk 1.9)

DefinitionCD-sens = basophil allergen threshold sensitivity (1/EC50 x 100)

Clinical implicationHigher CD-sens values indicate greater basophil sensitivity and lower threshold for reaction during OFC

inv-13: Competency requirement — tests to be undertaken by competent healthcare professionals

Competency requirementTests should only be undertaken by healthcare professionals with appropriate competencies to select, perform, and interpret them

Skin test facility requirementSkin tests should only be undertaken where there are facilities to manage an anaphylactic reaction

History prerequisiteDo not carry out allergy testing without first taking an allergy-focused clinical history

inv-14: Policy coding/capacity changes — policy updated with no change to clinical or coding criteria

Revision summaryPolicy updated for clarity with no change to clinical or coding criteria (per revision history)

LBM expansion noteLab Benefit Program expanded to additional EmblemHealth plan types effective 10/1/2024

Administrative changesCoverage Criteria reorganized and a clinical-only Coverage Criterion was removed without changing enforcement criteria

Note

Preferred diagnostic modalities and specialist referral — SPT and sIgE primary; CRD and specialized tests reserved for specialists

Skin prick testing (SPT) and serum allergen‑specific IgE (sIgE) testing are the preferred, first‑line diagnostic modalities for evaluation of IgE‑mediated allergic disease. SPT is quick, allows simultaneous testing of multiple allergens, and is generally preferred when safe and feasible; serum sIgE is a validated and effective alternative when SPT cannot be performed. Component‑resolved diagnostics (CRD) and other molecular or specialist tests may be useful in selected scenarios (for example, polysensitized patients, complex cross‑reactivity questions, or pre‑treatment assessment by specialists) and should generally be ordered or interpreted by allergy specialists. Total serum IgE may be useful in select circumstances (e.g., assessing atopic status or select asthma/ABPA evaluations) but should not be used routinely to diagnose food allergy.

Preferred modalities: Skin prick testing (SPT) and serum specific IgE (sIgE).
Specialist referral: Reserve CRD, advanced molecular testing, and complex interpretation for allergy/immunology specialists.
Total IgE: consider only in specific clinical contexts (moderate‑to‑severe asthma, suspected allergic bronchopulmonary aspergillosis), not as routine food allergy diagnosis.

Denial Risk

Non‑routine/adjunctive diagnostics — BAT, nasal sIgE, provocation testing not routine; reserved as adjuncts or specialist use

Adjunctive and non‑routine tests (including basophil activation test [BAT], nasal sIgE, nasal provocation testing, and oral/controlled provocation testing) are not indicated as routine first‑line diagnostics. These tests may be considered in select clinical or research settings or when standard diagnostics are inconclusive, and typically should be performed or interpreted by specialists with appropriate expertise. Avoid unproven or non‑validated tests (for example, IgG or IgG‑subclass testing for food allergy, multi‑allergen qualitative screens that do not identify specific allergens, bead‑based epitope assays lacking validation such as VeriMAP Peanut Dx, and antigen leukocyte antibody tests like ALCAT).

BAT, nasal sIgE, and provocation testing: consider only as adjuncts or when standard testing is not possible or yields conflicting results; typically specialist‑directed.
Do not use IgG/IgG subclass testing for food allergy diagnosis.
Do not use qualitative multi‑allergen screens that do not identify specific allergens.
Tests listed as not meeting coverage criteria (e.g., ALCAT, bead‑based epitope assays) are not supported due to lack of evidence.

inv-22: serum-specific IgE testing (sIgE) definition

DefinitionSpecific IgE immunoassays (serum-specific IgE; sIgE) — in vitro blood tests that detect allergen-specific IgE antibodies

IndicationsUseful when skin testing is unsafe or impractical (widespread dermatitis, interfering medications, uncooperative patients) and to identify suspected food allergens

LimitationsPresence of specific IgE alone does not confirm clinical allergy; results must be interpreted with clinical history

inv-23: SPT definition — skin prick testing

DefinitionSkin prick testing (SPT) — in vivo method to detect allergen-specific IgE by introducing standardized extracts into the skin

AdvantagesRapid, simple, cost-effective; correlates with challenge outcomes for many allergens

RequirementMust be interpreted by a clinician with adequate knowledge of medical history and performed where anaphylaxis can be managed

inv-24: BAT definition — basophil activation test measuring markers such as CD63/CD203c

DefinitionBasophil activation test (BAT) — a functional in vitro assay measuring basophil activation markers such as CD63 and CD203c after allergen stimulation

Clinical useMay confirm diagnosis in select food, venom, and respiratory allergies and can reduce need for oral food challenges in specialist settings

LimitationsCurrently nonstandardized in many settings; standardization and automation are needed for broader routine use

inv-25: SPT — alternate SPT definition entry

Alternate definitionSkin prick testing (SPT) — most frequently used method for detection of IgE antibodies because of rapidity, simplicity, and low cost

InterpretationResults must be interpreted with medical history, clinical findings, and knowledge of relevant regional allergens

Use casesIndicated for suspected food allergy, rhinitis, asthma, venom allergy, and select dermatologic conditions

inv-26: sIgE — serum allergen-specific IgE testing definition and use cases

DefinitionSerum allergen-specific IgE testing (sIgE) — in vitro measurement of specific IgE in serum used to detect sensitization

When preferredPreferred when SPT is unsafe or impractical (e.g., widespread skin disease, antihistamine use) or when skin testing poses higher anaphylaxis risk

Interpretation caveatsIgE indicates sensitization but is not alone diagnostic of clinical allergy; correlate with history and other testing

inv-27: CRD / molecular diagnostics definition — component resolved diagnostics purpose

DefinitionComponent-resolved diagnostics (CRD) / molecular diagnostics — testing for IgE to specific allergenic molecules (components) rather than whole extracts

PurposeCan increase diagnostic accuracy in certain scenarios, particularly in polysensitized patients and for risk assessment (e.g., Ara h 2 for peanut)

AccessTypically used by specialists; not routinely required when SPT or sIgE answers the clinical question

inv-28: BAT — note on nonstandardization and limited routine use

Note on standardizationBAT is established as a routine diagnostic in some specialized labs but remains nonstandardized; further standardization/automation is needed for broad routine use

Clinical roleUseful to confirm diagnosis in select allergies and as a second-step test after equivocal first-line testing to reduce oral food challenges

RecommendationNot recommended for routine use in general practice; consider in specialist settings when first-line tests are inconclusive

inv-29: LDT — laboratory-developed tests regulatory note

DefinitionLaboratory-developed tests (LDTs) — tests developed and validated in-house by laboratories

RegulationRegulated by CMS under CLIA as high-complexity tests; not approved or cleared by FDA though FDA approval is not required for clinical use currently

ImplicationLDTs require laboratory validation and proficiency testing; clinical use depends on demonstrated analytic validity

inv-30: Allergy-focused clinical history — requirement before testing

RequirementObtain an allergy-focused clinical history before performing allergy testing

PurposeHistory guides selection of allergens to test and interpretation of results

Testing guidanceChoose between SPT and sIgE based on the allergy-focused history, test suitability/safety for the patient, and available clinician competencies